Dermatologicals
Refine Search
Pharmaceutical
The boards of Switzerland-based Nestle, the world’s largest food company, and French cosmetics firm L’Oreal have approved a strategic transaction for both companies under which L’Oreal will buy 48.5 million of its own shares (8% of its share capital) from Nestle. 19 February 2014
Biotechnology
The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France, Germany, Italy, Spain, the UK and Japan - is expected to more than double in the near future, jumping from $5 billion in 2013 to $10.4 billion by 2020, at a significant compound annual growth rate (CAGR) of 11.1%, forecasts business intelligence provider GBI Research. 5 February 2014
Pharmaceutical
Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into a definitive agreement to acquire USA-based PreCision Dermatology, for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone. 3 February 2014
Biotechnology
Psoriasis drug Stelara (ustekinumab), from US health care giant Johnson & Johnson’s subsidiary Janssen Biotech, is set to become the leading brand among systemic treatments for psoriasis by 2017, according to independent analyst firm Datamonitor Healthcare. 30 January 2014
Pharmaceutical
Following the confirmation of the positive benefit-risk profile by the European Medicines Agency, German drug major Bayer says it is reintroducing its acne drug Diane-35 onto the French market in agreement with the French health authority (ANSM). 16 January 2014
Pharmaceutical
This week US drugmaker Allergan (NYSE: AGN) announced that it has closed a $65 million license agreement with South Korea’s Medytox and has gained marketing authorization for botulinum toxin (botox) in the UK. 9 January 2014
Pharmaceutical
US private equity firm Royalty Pharma says that it has acquired an additional interest in the earn-out payable to the former shareholders of Germany’s Fumapharm AG for $510 million in cash. 6 January 2014
Pharmaceutical
US biopharma management company NeXeption says it has secured $21.5 million in Series A financing to form Alexar Therapeutics, which is focused on developing an innovative portfolio of Liver X receptor (LXR) agonists for both systemic and local use. 3 January 2014
Pharmaceutical
US specialty pharma firm Everett Laboratories, a subsidiary of Spain’s Exeltis, has acquired Quinnova Pharmaceuticals, from parent company Amneal Enterprises, a privately-held US generic drugmaker. 27 December 2013
Pharmaceutical
Japanese drugmaker Kyowa Hakko Kirin and Denmark’s privately-held dermatology specialist LEO Pharma have entered into a distribution and co-promotion agreement for LEO’s proprietary topical calcipotriol/betamethasone dipropionate combination product. 26 December 2013
Pharmaceutical
Following regular monthly meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP; December 16-19), there were positive opinions for four investigational drugs issued on Friday. 22 December 2013
Pharmaceutical
Privately-held Italian drugmaker Angelini and Switzerland-based health care group Applied Pharma Research (APR) have entered into a strategic partnership to support and promote a novel and innovative product developed by APR for the management of a variety of wound conditions such as acute wounds, burns and advanced ulcers including venous and pressure ulcers and diabetic foot ulcers. 20 December 2013
Pharmaceutical
Spain’s largest drugmaker, Almirall says it has reached a definitive agreement to acquire Aqua Pharmaceuticals, a privately-held leading US-based prescription dermatology company. 17 December 2013
Pharmaceutical
Atopic dermatitis therapeutic sales in nine major global markets are forecast to increase from $3.9 billion in 2012 to $5.6 billion by 2022 according to research and consulting firm GlobalData. 15 November 2013
Biotechnology
Belgian biotech firm Galapagos says that a subsidiary has signed a three-year collaboration agreement with US biotech Biogen Idec focused on the identification and validation of novel targets in scleroderma. 13 November 2013
Generics
The Dubai-based Abraaj Group, an investor operating in global growth markets, has announced its full exit from Tunisian pharmaceutical company Opalia Pharma. 5 November 2013
Biotechnology
Clinical-stage US drug developer Rigel Pharmaceuticals has announced mixed updates on two of its pipeline products: R333, a topical dermatological JAK/SYK inhibitor, and fostamatinib, an oral SYK inhibitor, both of which were seen as promising for the company’s future. 25 October 2013
Pharmaceutical
US clinical-stage biopharmaceutical company Cellceutix says that it is completing the required documentation to begin a Phase IIb clinical trial of Brilacidin as a new drug candidate for acute bacterial skin and Skin structure infections. 14 October 2013
Pharmaceutical
Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib
Pfizer has announced mixed top-line results from two Phase III clinical trials of tofacitinib for the treatment of adults with moderate-to-severe chronic plaque psoriasis. 9 October 2013
Pharmaceutical
Novartis recently announced results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to US biotech leader Amgen’s Enbrel (etanercept) in moderate-to-severe plaque psoriasis. 8 October 2013
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze